Mindfulness in K-12 education: a case study approach exploring the implementation and sustainability of school mindfulness programs

Mindfulness practices are increasingly being implemented in schools across the United States. Due to the relatively nascent nature of the research on the impact of mindfulness on youth, it is critical to gain a deeper understanding of how mindfulness interventions work. Further, there is scant research on the implementation and sustainability of school mindfulness programs. This deficit in our knowledge makes it difficult to understand the process of bringing mindfulness programs into schools, preventing researchers and practitioners from ascertaining how implementation affects outcomes. This qualitative study is comprised of two case studies that explore the goals, successes, and challenges of implementing school mindfulness programs. The first case features a non-profit organization that provides mindfulness programming to school districts; the second focuses on the perspectives of administrators, teachers, guidance counselors, and mental health professionals from a school district that has employed mindfulness practices for over a decade. Findings suggest that implementing mindfulness practices in schools is a complex process involving multiple stakeholders, significant planning, staff training, and noteworthy challenges, such as the lack of clarity when defining program goals

Anxiety in older adults with dementia residing in long-term care facilities.

Dementia, depression, and anxiety are the most common psychiatric disorders among long-term care residents and, because dementia is associated with behavioral problems that can be difficult to manage, the growing number of long-term care residents with dementia and mental health disorders presents a challenge for providing quality care. Research has established the co-occurrence of depression and anxiety and anxiety and agitation in this population. However, a consensus on the conceptualization of the co-occurrence of these constructs has not been reached. It has also been postulated that older adults with dementia may not be able to experience anxiety as conceptualized due to cognitive impairment. Many older adults with anxiety report having anxiety throughout their lives, suggesting those with dementia would continue to experience anxiety despite cognitive decline. The purpose of this study is to examine the relationships among depression, anxiety, and agitation in long-term care residents with dementia emphasizing the roles of cognitive functioning and mental health history. Residents (N = 65) completed measures of mental health history, anxiety, and affect, while their nursing assistants completed measures of anxiety and agitation. Measures of depression and cognitive functioning were gathered from Minimum Data Sets. Confirmatory factor analyses and factorial ANOVAs were used to test the hypotheses. The results demonstrated depression, anxiety, and agitation in long-term care residents with dementia represented an overarching construct of distress. Significant relationships existed between current anxiety and agitation, as well as history of anxiety and current anxiety, irrespective of cognitive functioning. The results of this study suggest depression and anxiety in long-term care residents with dementia may be structurally different than in younger adults and other older adult populations. Differentiating agitation from other indicators of affective distress was not possible in this sample. Instead, depression, anxiety, and agitation may all be manifestations of a global construct of distress associated with dementia. Nevertheless, history of anxiety disorder was a predictor of current anxiety. The continuity of anxiety across the lifespan, maintenance of anxiety throughout the progression of dementia, and risk for increased co-morbidity highlights the need for screening for anxiety in long-term care facilities to provide optimal care

HoxA9 binds and represses the Cebpa +8 kb enhancer

C/EBPα plays a key role in specifying myeloid lineage development. HoxA9 is expressed in myeloid progenitors, with its level diminishing during myeloid maturation, and HOXA9 is over-expressed in a majority of acute myeloid leukemia cases, including those expressing NUP98-HOXD13. The objective of this study was to determine whether HoxA9 directly represses Cebpa gene expression. We find 4-fold increased HoxA9 and 5-fold reduced Cebpa in marrow common myeloid and LSK progenitors from Vav-NUP98-HOXD13 transgenic mice. Conversely, HoxA9 decreases 5-fold while Cebpa increases during granulocytic differentiation of 32Dcl3 myeloid cells. Activation of exogenous HoxA9-ER in 32Dcl3 cells reduces Cebpa mRNA even in the presence of cycloheximide, suggesting direct repression. Cebpa transcription in murine myeloid cells is regulated by a hematopoietic-specific +37 kb enhancer and by a more widely active +8 kb enhancer. ChIP-Seq analysis of primary myeloid progenitor cells expressing exogenous HoxA9 or HoxA9-ER demonstrates that HoxA9 localizes to both the +8 kb and +37 kb Cebpa enhancers. Gel shift analysis demonstrates HoxA9 binding to three consensus sites in the +8 kb enhancer, but no affinity for the single near-consensus site present in the +37 kb enhancer. Activity of a Cebpa +8 kb enhancer/promoter-luciferase reporter in 32Dcl3 or MOLM14 myeloid cells is increased ~2-fold by mutation of its three HOXA9-binding sites, suggesting that endogenous HoxA9 represses +8 kb Cebpa enhancer activity. In contrast, mutation of five C/EBPα-binding sites in the +8 kb enhancer reduces activity 3-fold. Finally, expression of a +37 kb enhancer/promoter-hCD4 transgene reporter is reduced ~2-fold in marrow common myeloid progenitors when the Vav-NUP98-HOXD13 transgene is introduced. Overall, these data support the conclusion that HoxA9 represses Cebpa expression, at least in part via inhibition of its +8 kb enhancer, potentially allowing normal myeloid progenitors to maintain immaturity and contributing to the pathogenesis of acute myeloid leukemia associated with increased HOXA9

Sitting and Supine Esophageal Pressures in Overweight and Obese Subjects Authors

Esophageal pressure can be used to approximate pleural pressure and might be clinically useful, particularly in the obese e.g to guide mechanical ventilator settings in critical illness. However, mediastinal artifact (the difference between true pleural pressure and esophageal pressure) may limit acceptance of the measurement, and reproducibility of esophageal pressure measurements remains unknown. Therefore, we aimed to assess the effect of body posture on esophageal pressure in a cohort of obese but healthy subjects, some of whom had multiple measurements, to address the clinical robustness of esophageal manometry. Twenty-five overweight and obese subjects (BMI>25kg/m2) and 11 control lean subjects (BMI<25kg/m2) underwent esophageal manometry with pressures measured seated and supine. Twenty overweight and obese subjects had measurements repeated after ~1-2 weeks. Anthropometric data and sitting and supine spirometry were recorded. The average end-expiratory esophageal pressures sitting and supine were greater in the overweight and obese group than the lean group (sitting −0.1±2.1 vs. −3.3±1.2cmH2O, supine 9.3±3.3 vs. 6.9±2.8cmH2O, respectively). The mean differences between repeated measurements were small (−0.3 ± 1.7cmH2O sitting and −0.1 ± 1.5cmH2O supine). Esophageal pressures correlated with a number of anthropometric and spirometric variables. In conclusion, esophageal pressures are slightly greater in overweight and obese subjects than lean subjects; but changes with position are similar in both groups. These data indicate that mediastinal weight and postural effects on esophageal pressure are within a clinically acceptable range, and suggest that esophageal manometry can be used to inform clinical decision making across wide range of body types

The Student Movement Volume 107 Issue 1: We\u27re Back: Andrews Begins First Post-Covid School Year

HUMANS Interview of NEST performer: Sandrine Adap, Interviewed by: Nora Martin Meet Helena Hilton!, Interviewed by: Nora Martin Meet Aya Pagunsan, AUSA President, Interviewed by: Lauren Kim ARTS & ENTERTAINMENT Currently..., Solana Campbell Film and a Fling, Jonathon Woolford-Hunt Fleabag: Simply Human, Lily Rodriguez Summer Rewind, Ysabelle Fernando NEWS Andy\u27s Welcome Back Party, Gloria Oh News Analysis: Gun Violence in Cities, Julia Randall What\u27s New? Genesis Fellowship, Lauren Butler IDEAS Bring Balance to the Forest, Alexander Navaro In Rebuttal of Andrew Tate, Elizabeth Getahun Student Loan Forgiveness, Gabriela Francisco The Death of Her Majesty Queen Elizabeth II: The Right to Mourn (and Not), Alexander J. Hess PULSE Campus Life After Covid-19: A Newfound Freedom, Amelia Stefanescu Environmental Fridays Begins a New Season, Princella Tobias Freshmen Advice, Gloria Oh What to Eat in a Small Town, Lexie Dunhamhttps://digitalcommons.andrews.edu/sm-107/1000/thumbnail.jp

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

BackgroundWe performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours.MethodsPatients were given fixed dose gemcitabine plus increasing doses of nab-paclitaxel and bevacizumab. Toxicity, response, and association with VEGF polymorphism was analysed.ResultsThe study enrolled 110 patients who had undergone a median of 3 prior lines of therapy. The median age was 60 years (range, 17-85 years), and 55 patients (50%) had gemcitabine-refractory disease. We observed 3 dose-limiting toxicities during dose escalation and 3 DLTs in expansion cohorts. Dose escalation to 150 mg/m2 nab-paclitaxel and 15 mg/kg bevacizumab with 1000 mg/m2 of gemcitabine was well tolerated with no MTD. One patient with gemcitabine-refractory peritoneal papillary carcinoma had a complete response, 13 patients (13%) had partial responses, and 54 patients (52%) had stable disease ≥12 weeks. Exploratory VEGF single nucleotide polymorphism (SNP) analysis was performed on 13 patients.ConclusionsThe combination of gemcitabine, nab-paclitaxel, and bevacizumab is safe, well-tolerated, and has activity in advanced malignancies, including gemcitabine-refractory tumours. Based on this study, the recommended phase 2 dose is gemcitabine 1000 mg/m2, nab-paclitaxel 125 mg/m2, and bevacizumab 15 mg/kg. VEGF polymorphism data should be evaluated in future bevacizumab-based trials

PU.1 opposes IL-7-dependent proliferation of developing b cells with involvement of the direct target gene bruton tyrosine kinase

Deletion of genes encoding the E26 transformation-specific transcription factors PU.1 and Spi-B in B cells (CD19-CreΔPB mice) leads to impaired B cell development, followed by B cell acute lymphoblastic leukemia at 100% incidence and with a median survival of 21 wk. However, little is known about the target genes that explain leukemogenesis in these mice. In this study we found that immature B cells were altered in frequency in the bone marrow of preleukemic CD19-CreΔPB mice. Enriched pro-B cells from CD19-CreDPB mice induced disease upon transplantation, suggesting that these were leukemia-initiating cells. Bone marrow cells from preleukemic CD19-CreΔPB mice had increased responsiveness to IL-7 and could proliferate indefinitely in response to this cytokine. Bruton tyrosine kinase (BTK), a negative regulator of IL-7 signaling, was reduced in preleukemic and leukemic CD19-CreΔPB cells compared with controls. Induction of PU.1 expression in cultured CD19-CreΔPB pro-B cell lines induced Btk expression, followed by reduced STAT5 phosphorylation and early apoptosis. PU.1 and Spi-B regulated Btk directly as shown by chromatin immunoprecipitation analysis. Ectopic expression of BTK was sufficient to induce apoptosis in cultured pro-B cells. In summary, these results suggest that PU.1 and Spi-B activate Btk to oppose IL-7 responsiveness in developing B cells

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Answer questions and earn CME/CNETo update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8‐1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors “microscopic” and “macroscopic” for regional node metastasis are redefined as “clinically occult” and “clinically apparent”; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA‐IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in‐transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor‐involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence‐based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472‐492. © 2017 American Cancer Society.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139981/1/caac21409_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/139981/2/caac21409-sup-0001-suppinfo01.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/139981/3/caac21409.pd

The Gallery 2007

This is a digital copy of the print book produced by the Gallery 2007 team. Contents: p. 4 Introduction, p. 6 Photography, p. 14 Illustration, p. 28 Graphic Design, p. 44 Painting, p. 50 Three Dimensional, p. 62 Printmaking, p. 82 Autographs, p. 84 Index. Files for individual sections may be viewed on the detailed metadata page by clicking on the book title.https://rdw.rowan.edu/the_gallery/1008/thumbnail.jp

Effect of Dupilumab on Sleep Apnea Severity in Patients With Chronic Rhinosinusitis

Patients with chronic rhinosinusitis (CRS) report improved sleep quality after dupilumab, an anti IL4/13 therapy. Concurrent CRS and obstructive sleep apnea (OSA) cases are not rare, and CRS seemingly raises nasal resistance. Thus, we hypothesized that improved sleep quality by dupilumab therapy in CRS patients might be due to lowered nasal resistance and subsequent improvement of unrecognized comorbid OSA. Patients with concurrent CRS and OSA were recruited. Nasal resistance was measured invasively with transnasal pressure and flow data collected during normal respiration in the supine position. Results from the first five participants did not support our hypothesis. Subjective and objective measures for CRS and nasal resistance values were improved with dupilumab therapy in CRS patients with nasal polyps. However, apnea severity and sleep-related subjective parameters did not change. In the patients with CRS without nasal polyps, no significant changes in either CRS or OSA-related measures were observed